2.46 (-%)
As of Nov 29, 2024
Source:
We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal (“GI”) tract. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.
Country | United States |
Headquarters | carlsbad, california |
Phone Number | (858) 704-4900 |
Industry | manufacturing |
CEO | J.D. Finley |
Website | www.clinicaltrials.gov |